Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England
Menée en Angleterre à partir de données de vie réelle portant sur 1 665 patients atteints d'un cancer du poumon non à petites cellules de stade localement avancé ou métastatique, cette étude compare l'efficacité, du point de vue de la survie globale, du délai avant le prochain traitement ou le décès, du sotorasib et du docétaxel en traitement de deuxième ligne ou plus
Purpose: To compare sotorasib versus docetaxel monotherapy real-world outcomes in second line and beyond (2 L+) for locally advanced or metastatic non-small cell lung cancer (NSCLC).
Methods: The Cancer Analysis System includes English registration data. Sotorasib-treated patients with KRAS G12C-mutated NSCLC were compared with docetaxel-treated patients with NSCLC. Outcomes included overall survival (OS), time to next treatment or death (TTNTD), and time to treatment discontinuation or death (TTDD). The study period was 01 January 2013‒31 May 2024. The index date was the earliest date of initiation of sotorasib (01 March 2021–31 May 2024) or docetaxel monotherapy (01 January 2017‒31May 2024) in 2 L+. Propensity score weighting balanced baseline characteristics.
Results: The analysis included 1,665 patients (394 sotorasib; 1,271 docetaxel). Adjusted median OS was 10.18 months (95% confidence interval [CI]: 9.10‒12.02) with sotorasib and 6.87 (95% CI: 6.01‒7.82) with docetaxel (P < 0.001); risk of death decreased by 36.7% with sotorasib (hazard ratio [HR]: 0.633; 95% CI: 0.536‒0.749; P < 0.001). Adjusted median TTNTD was 8.51 (95% CI: 7.33‒9.43) and 5.62 months (95% CI: 5.06, 6.18) with sotorasib and docetaxel, respectively (P < 0.001); risk of initiation of a new line of therapy or death was decreased by 43.3% with sotorasib (HR: 0.567; 95% CI: 0.485, 0.663; P < 0.001). Adjusted median TTDD was 5.06 (95% CI: 4.34‒6.11) and 2.30 months (95% CI: 2.07, 2.76) with sotorasib and docetaxel, respectively (P < 0.001).
Conclusion: Sotorasib was associated with significantly improved OS, TTNTD, and TTDD compared with docetaxel in 2 L+ for locally advanced or metastatic NSCLC under real-world conditions in England.
Lung Cancer , résumé, 2026